H.C. Wainwright would be surprised if Sarepta elects to dose higher in LGMD2E

H.C. Wainwright analyst Debjit Chattopadhyay notes that Sarepta’s preliminary LGMD2E data at 25% the dose being used in the ongoing micro-dystrophin registration study exceeded expectations. With protocol modification that now reflect 60-day course of steroids, the safety profile is likely to be acceptable for a one-time treatment, which appears to deliver consistent outcomes in both pediatric and adolescent patients, he adds. With an “eye on safety and COGS,” the analyst would be surprised if Sarepta elects to dose higher. Chattopadhyay expects the stock to work higher through the remainder of the year with two large market opportunity gene therapy programs “likely in the bag” and more to follow, a compelling and growing commercial franchise behind Exondys 51, and a disease segment solidifying update expected from SRP-5051. He

https://thefly.com/landingPageNews.php?id=2871414